Pandemic prescribing: were older heart patients given dangerous drugs?
NCT ID NCT05336565
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at medical records of 1,000 older heart patients in Russia to see if they were prescribed potentially harmful medications during the COVID-19 pandemic. Researchers will use a medical database to count how often these risky prescriptions happened and check for dangerous drug combinations. The goal is to understand and improve medication safety for elderly heart patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors avoid prescribing unsafe medications to older heart patients during future health crises.
- What could go wrong
- This is an observational study using existing records, so it cannot prove cause and effect. Results may not apply to other regions or healthcare systems.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2022
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Cardiovascular patients enrolled in the reimbursement program in Tomsk Region who have electronic medical records stored in medical information system BARS.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * established diagnosis of cardiovascular disease * age of 18 years and older * enrollment in the reimbursement program in Tomsk Region Exclusion Criteria: * age of 17 years and younger
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiovascular disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Tomsk NRMC
RECRUITINGTomsk, 634012, Russia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Tailored heat warnings shield chronic disease patients from dangerous temperatures?
- Can calming inflammation shield the heart?
- Could artery disease drain the body's repair cells?
- Can hidden blood mutations ignite heart disease?
- Could tiny heart vessels hold the key to a common form of heart failure?
- Could an old malaria drug shield hearts in kidney disease?